personalized cancer care

See the following -

EKF Announces Collaboration with ANGLE on Open Source Parsortix Liquid Biopsy for Cancers

Press Release | EKF Diagnostics, ANGLE plc | January 23, 2015

ANGLE’s patented Parsortix system can harvest very rare CTCs in cancer patient blood – even when there is less than one CTC in one billion healthy cells.  The resulting liquid biopsy (simple blood test) enables the investigation of mutations in the patient’s cancer for personalised cancer care.  The Parsortix system is “open-source” and has been designed to work with all existing analytical procedures in the same way that the existing solid biopsy provides cancer cells for a wide variety of analytical procedures.

Read More »

VA, DOD, NCI Partner for Precision Medicine Tumor Screening

Nathan Boroyan | Health IT Analytics | August 26, 2016

A new precision medicine partnership between the Department of Veterans Affairs (VA), the Department of Defense (DoD) and the National Cancer Institute (NCI) will create the nation's first system that routinely screens tumors for gene and protein information in hopes of providing targeted, individualized therapies. The new program, the Applied Proteogenomics Organizational Learning and Outcomes consortium (APOLLO), is part of the Cancer Moonshot Initiative...

Read More »